More Than a CDMO
The End-to-End Support of Your Portfolio
Pre-Clinical
Partner with us for cell line and strain development, manufacturability assessments, cell banking and toxicology material generation. Let us guide your path to IND/IMPD submission.
Clinical Phase I, II
Partner with us to develop your initial clinical process for cGMP drug substance and drug product manufacturing.
Clinical Phase III
Partner with us to optimize, scale and characterize your process to meet anticipated therapeutic demands.
Commercialization
Partner with us for process validation and process performance qualification. Leverage our CMC and regulatory services for your BLA/MAA submission and experience our reliability.
Setting New Standards in
Tomorrow’s Medicines
0
Billion USD Invested
in recent years
Spotlight
Press Releases
FUJIFILM Diosynth Biotechnologies Celebrates Opening of the Latest Manufacturing Expansion – a Major Boost to Danish Life Science
HILLERØD, DENMARK, January 9, 2025 — The Danish life science industry is getting yet another boost as FUJIFILM Diosynth Biotechnologies celebrates its recent production expansion in Denmark.
Press Releases
FUJIFILM Diosynth Biotechnologies Celebrates the Expansion Completion at its California Cell Therapy Facility
THOUSAND OAKS, CALIF., November 20, 2024 – FUJIFILM Diosynth Biotechnologies today hosted a celebration for the completion of an expansion of its cell therapy manufacturing facility in Thousand Oaks, California.
Press Releases
FUJIFILM Diosynth Biotechnologies Launches First Phase of Global CDMO Ecosystem Expansion
HILLERØD, DENMARK, November 5, 2024 – FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, advanced therapies, and oncolytic viruses, proudly announces that the first phase of its expansion at the Hillerød site is ready to bring the new production capacity into operation.
Press Releases
FUJIFILM Diosynth Biotechnologies Signs Manufacturing Supply Agreement With TG Therapeutics
HOLLY SPRINGS, N.C., November 4, 2024, FUJIFILM Diosynth Biotechnologies, a world leading CDMO, today announced that TG Therapeutics, Inc. (NASDAQ: TGTX) has committed to a multi-year manufacturing supply agreement for BRIUMVI® (ublitiximab-xiiy), its U.S. FDA-approved therapeutic for relapsing forms of multiple sclerosis (RMS).
